Final scheme & Syllabus for M. Pharm course implemented from 2016-17 academic session

-

Pharmacy Council of India (PCI) has published final scheme & Syllabus for M. Pharm course implemented from 2016-17 academic sessions. This syllabus is based on notification in the gazette of India no. 362, dated December 11th 2014.

The full text syllabus is available at http://www.pci.nic.in/CollegesCourses/Syllabus_M_Pharm.pdf

As pharmabiz reports here: http://www.pharmabiz.com/NewsDetails.aspx?aid=98755&sid=1

The new M Pharm syllabus will be more of practical oriented rather than theory and the students will have an option to work with the industry and get a practical experience along with the stipend.

The new syllabus is all set and will appear on the PCI website since November 17, 2016. The council has assured that the new syllabus will benefit the students as well as the industry.

Dr B Suresh, president of PCI says, "The new syllabus of M Pharm is a new approach to postgraduate education. The two-year course will include a theory based education, in the first year and in the second year we have included non thesis as an option to research project. So the student can opt either for a non thesis or research project for one year. The benefit of non thesis is that the student will get a real practical experience during their course duration itself and the industry can also utilise the human resources and get the best of it."

The PCI will also have a tie-up with the industry for the recruitment of the M Pharm students in the coming days. Along with DCGI, the council is planning a meeting with the industry associations regarding the non thesis option included in the M Pharm syllabus. It will also request the industry to provide stipends to the students so that they are not exploited and later on if the companies want they can also recruit them.

“We have made a committee which will be working on the tie-ups with the industry. We will be meeting the industry associations like IDMA, IPA, CIPI etc. in the month of January or February”, said Dr Suresh.

Comments

Post a Comment

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

-
The China-India joint summit held recently discussed bilateral trade to improve Indo- China pharma industry and address issues like long product registration time and high fees for product registration in China’s drug regulatory system, among other issues.  Besides this, other relevant key issues related to transparency in public procurement system in China and clinical trial related approvals were also deliberated at the summit organised under the aegis of Indian Pharmaceutical Association (IPA), Shengjie and SaSPinjara, China between May 16 and May 17, 2019 at Pullman Shanghai South, China. The summit was focused on enhancing export business for both the nations across the globe. Senior health ministry official from Government of Gujarat Punamchand Parmar was invited as the Chief Guest of the summit and Gujarat Food and Drugs Control Administration (FDCA) Commissioner Dr Hemant Koshia was invited as Guest of Honour.  Among other dignitaries, Dr. Anil Kumar Rai, Consulate General of
Read more

Webinar on ‘OPPORTUNITY TO COMMERCIALIZE HERBAL RESEARCH’

-
Image
“IDEA TO MARKET” is an idea hunt to commercialize the herbal inventions. It is a platform for researchers to use their innovative ideas in the area of herbal research and get the products commercialized in collaboration with corporate partners.  Hurry up and register for the webinar to know more about this program. The webinar is organized by Bombay College of Pharmacy and Pharma Literati.  Registration Link for webinar on OPPORTUNITY TO COMMERCIALIZE HERBAL RESEARCH: https://docs.google.com/forms/d/e/1FAIpQLSfUhe1LtCOjG50SilFw_iECnzBXu4CW0nK2wIvd8QVVvpDOzQ/viewform
Read more